NDAINJECTIONINJECTABLE
Approved
Sep 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 6h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
GENESA (arbutamine hydrochloride) is an injectable synthetic catecholamine approved in 1997 for diagnostic stress testing in patients unable to exercise. It mimics the cardiac stress response by stimulating beta-adrenergic receptors to increase heart rate and contractility, enabling non-invasive assessment of coronary artery disease.
LOE Approaching
Product approaching loss of exclusivity with minimal competitive pressure (30/100), indicating a mature, declining commercial footprint with likely reduced team resources.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
GENESA currently shows zero linked job openings, reflecting its late-lifecycle stage and minimal commercial expansion. Careers on this product are best suited for professionals seeking stable, diagnostic-focused roles rather than growth-oriented positions.
Brand ManagerField Sales Representative
Worked on GENESA at AutoMedicus? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.